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Multidrug resistance, a major problem that leads to failure of anticancer chemotherapy,
requires the development of new drugs. Repurposing of established drugs is a promising
approach for overcoming this problem. An example of such drugs is niclosamide, a
known anthelmintic that is now known to be cytotoxic and cytostatic against cancer
cells. In this study, niclosamide showed varying activity against different cancer cell
lines. It revealed better activity against hematological cancer cell lines CCRF-CEM,
CEM/ADR5000, and RPMI-8226 compared to the solid tumor cell lines MDA-MB-231,
A549, and HT-29. The multidrug resistant CEM/ADR5000 cells were similar sensitive
as their sensitive counterpart CCRF-CEM (resistance ration: 1.24). Furthermore,
niclosamide caused elevations in reactive oxygen species and glutathione (GSH) levels in
leukemia cells. GSH synthetase (GS) was predicted as a target of niclosamide. Molecular
docking showed that niclosamide probably binds to the ATP-binding site of GS with a
binding energy of −9.40 kcal/mol. Using microscale thermophoresis, the binding affinity
between niclosamide and recombinant human GS was measured (binding constant:
5.64 µM). COMPARE analyses of the NCI microarray database for 60 cell lines showed
that several genes, including those involved in lipid metabolism, correlated with cellular
responsiveness to niclosamide. Hierarchical cluster analysis showed five major branches
with significant differences between sensitive and resistant cell lines (p = 8.66 × 105).
Niclosamide significantly decreased nuclear factor of activated T-cells (NFAT) activity
as predicted by promoter binding motif analysis. In conclusion, niclosamide was
more active against hematological malignancies compared to solid tumors. The drug
was particularly active against the multidrug-resistant CEM/ADR5000 leukemia cells.
Inhibition of GSH synthesis and NFAT signaling were identified as relevant mechanisms
for the anticancer activity of niclosamide. Gene expression profiling predicted the
sensitivity or resistance of cancer cells to niclosamide.
Keywords: chemotherapy, pharmacogenomics, drug resistance, transcription factors, oxidative stress
Abbreviations: ABC, ATP-binding cassette; GS, glutathione synthetase; GSH, glutathione; MDR, multidrug resistance;
NFAT, nuclear factor of activated T-cells; Pgp, P-glycoprotein; ROS, reactive oxygen species.
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INTRODUCTION
Niclosamide, an anthelmintic drug that has been used for
about 50 years, is known to be safe and well tolerated.
Niclosamide has been identified as a potential anticancer agent
that exerts cytotoxic and cytostatic activity against a wide range of
cancer types, including leukemia, breast cancer, prostate cancer,
hepatocellular carcinoma, and glioblastoma. Additionally it has
shown anti-invasive and anti-migratory effects. Several signaling
pathways are inhibited by niclosamide in cancer cells including
the Wnt/β-catenin, mechanistic target of rapamycin complex 1
(mTORC1), signal transducer and activator of transcription 3
(STAT3), nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB), and Notch pathways (Li et al., 2014).
Multidrug resistance (MDR) is a major problem in cancer
patients that leads to failure of chemotherapy. It affects most
cancers and is characterized by cross-resistance to a wide range of
commonly used chemotherapeutic drugs (Bartsevich and Juliano,
2000). Most cancers consist of a mixture of heterogeneous
malignant cells. Some of them are drug-sensitive and others are
drug-resistant. As a result, chemotherapeutic agents mostly kill
sensitive cells, but leave out a great proportion of resistant cell
populations. Therefore, recurrent tumors are frequently resistant
with fatal consequences for the patients (Housman et al., 2014).
Of the various mechanisms that contribute to MDR in cancer,
the increased eﬄux of drugs by the ATP-binding cassette (ABC)
transporters is the most encountered. The most important of
these transporters is P-glycoprotein (Pgp; Bellamy, 1996).
Elevated levels of reactive oxygen species (ROS) occur
in almost all types of cancer. They are involved in the
promotion of tumor development and progression (Storz,
2005). Cancer cells also express increased levels of antioxidants
to detoxify ROS. The process of ROS detoxification is
facilitated either through antioxidant enzymes, which scavenge
different types of ROS, or by non-enzymatic molecules.
Antioxidant enzymes include catalase, superoxide dismutase, and
peroxiredoxins. Non-enzymatic antioxidants include glutathione
(GSH), flavonoids, vitamins A, C, and E (Liou and Storz, 2010).
Treatment of cancer cells with vitamin E and vitamin C (ROS
scavengers) increased the expression of Pgp. This suggests that
Pgp-mediated MDR can be circumvented under conditions of
elevated ROS levels. One of the compounds that elevate ROS
levels in cancer cells is niclosamide. ROS generation plays an
important role in the anticancer activity of niclosamide in acute
myeloid leukemia and lung cancer cells (Wartenberg et al., 2005;
Jin et al., 2010; Lee et al., 2014).
The ultimate goal of drug development is to identify molecules
with the desired effect in the human body and to establish
its quality, safety, and efficacy for treating patients (Kraljevic
et al., 2004). Drug development, starting with the initial
discovery of a promising target to the final marketed medication,
is an expensive, lengthy, and incremental process (Hoelder
et al., 2012). An alternative approach is drug repositioning
or repurposing, in which new indications are found for
existing drugs. The advantages of this approach is that the
pharmacokinetics, pharmacodynamics, and toxicity profiles of
the investigated drugs are already known. If successful, this leads
to a great reduction in time and money expenditures for the
evaluation of drugs during preclinical and clinical development
(Ashburn and Thor, 2004; Tada et al., 2006).
In order to evaluate the usefulness of niclosamide for MDR,
we investigated its activity on the sensitive CCRF-CEM and the
MDR (Pgp overexpressing) CEM/ADR5000 leukemia cells. As
niclosamide is known to elevate ROS levels in cancer cells, we also
tested its effect on ROS generation in both cell lines. Furthermore,
we have attempted to identify the molecular mechanisms of
action of niclosamide, by microarray-based analyses.
MATERIALS AND METHODS
Cell-Lines
CCRF-CEM and CEM/ADR5000 leukemia, RPMI-8226 multiple
myeloma, and HT-29 colorectal cancer cells were grown in RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS),
penicillin (100 U/ml)/streptomycin (100 µg/ml) in a 5% CO2
atmosphere at 37◦C. MDA-MB-231 breast cancer and A549 lung
cancer cells were grown in Dulbecco’s Modified Eagle’s Medium
supplemented with 10% FBS, penicillin (100 U/ml)/streptomycin
(100 µg/ml) in a 5% CO2 atmosphere at 37◦C. Cells were
passaged twice weekly. Resistance of CEM/ADR5000 was
maintained by treatment with 5000 ng/ml doxorubicin for 24 h
every 2 weeks. All experiments were performed with cells in the
logarithmic growth phase.
Cytotoxicity Assay
Cells obtained from exponential phase cultures were counted and
seeded into 96-well plates. The seeding density was 104 cells per
well for both cell lines. Cells were then exposed to niclosamide
(Sigma-Aldrich, Taufkirchen, Germany) using 0.001, 0.01, 0.1, 1,
10, and 100 µM, in all cell lines. After a 72 h incubation period,
20 µl of resazurin 0.01% w/v was added to each well and the
plates were incubated at 37◦C for 4 h. Fluorescence was measured
using an Infinite M2000 Pro plate reader (Tecan, Crailsheim,
Germany). Dose–response curves were generated by plotting
the mean cell viability (%) against the concentration of the
compound (µM). IC50 values were calculated from a calibration
curve by linear regression using Microsoft Excel. The resistance
ratio for sensitive CCRF-CEM and resistant CEM/ADR5000 cells
was calculated by: IC50 resistant/IC50 sensitive. Experiments were
repeated three times.
ROS Assay
For each sample 2 × 106 cells were seeded in each well of a six-
well plate. Each well was treated with 1.5 µM of niclosamide or
dimethyl sulfoxide (DMSO). After 24 h incubation, cells were
centrifuged and resuspended in RPMI-1640 culture medium and
incubated with 10µM 2′,7′-dichlorodihydrofluorescein-diacetate
(H2DCFH-DA) for 20 min in the dark. Subsequently, cells
were centrifuged, washed with phosphate buffered saline (PBS),
resuspended in culture medium and measured in a BD-C6 flow
cytometer (Becton-Dickinson, Heidelberg, Germany). Cells were
also treated with H2O2 for 15 min as a positive control. For
each sample, 1× 104 cells were counted. 2′,7′-dichlorofluorescein
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(DCF) was measured at 488 nm excitation and detected using a
530/30 nm bandpass filter. The experiment was repeated three
times.
Target Prediction
The structure of niclosamide was obtained from ChemSpider1
and saved as a mol file. The compound was then submitted to
the DRAR-CPI software2. The protein targets showing the highest
docking scores were obtained.
Glutathione Assay
The levels of GSH were determined after the treatment of cells
with 0.75, 1.5, 3, 6, and 12 µM niclosamide, and incubated for
24 h at 37◦C. The cells were then centrifuged and suspended
in PBS supplemented with 5% FBS. The cells were stained
with 40 µM monochlorobimane and incubated for 20 min.
Fluorescence was read using an LSR-Fortessa flow cytometer
(Becton-Dickinson, Heidelberg, Germany) using a 405 nm laser.
The experiment was repeated three times.
Molecular Docking
The PDB file for the crystal structure of GSH synthetase (GS)
(PDB ID: 2HGS) was downloaded from the protein data bank3.
To perform molecular docking, the protein structure of GS
were first processed with AutodockTools-1.5.6rc316 to overcome
problems of incomplete structures due to missing atoms or
water and the presence of multimers or interaction partners
of the receptor molecule. The output file after preparation was
set in PDBQT format, where information about atomic partial
charges, torsion degrees of freedom and different atom types were
added, e.g., aliphatic and aromatic carbon atoms or polar atoms
forming hydrogen bonds. A grid box was then constructed to
define docking spaces. The dimensions of the grid box were set
around the entire protein molecule in a manner that the ligand
could freely move and rotate in the docking space. The grid box
consisted of 126 grid points in all three dimensions (X, Y, and Z)
separated by a distance of 1 Å between each one. Energies at each
grid point were evaluated for each atom type present in the ligand,
and the values were used to predict the energy of a particular
ligand configuration. Docking parameters were set to 250 runs
and 2,500,000 energy evaluations for each cycle. Docking was
performed for niclosamide on GS using Autodock4 by means of a
Lamarckian algorithm. The corresponding binding energies and
the number of conformations in each cluster were attained from
the docking log files (dlg). The process was repeated in a triplicate.
The mean and standard deviation were calculated.
Microscale Thermophoresis
The interaction between recombinant human GS (Abcam,
Cambridge, UK) and niclosamide was studied using microscale
thermophoresis as previously described (Seo and Efferth, 2016).
Protein was labeled according to the MonolithTM NT.115
Protein Labeling Kit BLUE-NHS (Amine reactive; NanoTemper
1http://www.chemspider.com
2https://cpi.bio-x.cn/drar
3http://www.rcsb.org/pdb
Technologies GmbH, Munich, Germany). The labeled human
GS was titrated with niclosamide. The final concentrations of
niclosamide were 200, 100, 50, 25, and 3.125 µM in analysis
buffer (50 mM Tris buffer pH 7.6 containing 150 mM NaCl,
10 mM MgCl2, and 0.05% Tween-20). Samples were analyzed
using hydrophilic capillaries in NanoTemper MonolithTM NT
(NanoTemper Technologies GmbH, Munich, Germany) for blue
dye fluorescence.
COMPARE Analyses
The mRNA microarray data of the NCI tumor cell line panel
available at the NCI website4 was used (Scherf et al., 2000;
Staunton et al., 2001). COMPARE analyses were performed to
produce rank-ordered lists of genes expressed in the NCI cell
lines as previously described (Paull et al., 1989; Wosikowski et al.,
1997). Briefly, every gene of the NCI microarray database was
ranked for similarity of its mRNA expression to the log10IC50
values for niclosamide. To derive COMPARE rankings, a scale
index of correlation coefficients (R-values) was created.
Hierarchical Cluster Analysis
Hierarchical cluster analysis was performed, in order to create
a cluster model for the different cell lines. This was done
by classifying objects into dendrograms. The distances were
calculated according to the closeness of between-individual
distances. Cluster models have previously been validated for
gene expression profiling and for approaching molecular
pharmacology of anticancer agents (Efferth et al., 1997; Scherf
et al., 2000).
Promoter Binding Motif Analysis
Binding motifs for transcription factors in the promoter
sequences of genes were analyzed by Cistrome analysis software
(Liu et al., 2011). Briefly, genes of interest were retrieved in BED
format from https://genome.ucsc.edu/cgi-bin/hgTables. SeqPos5
was used to screen for enriched transcription factor binding
motifs in gene promoter sequences. The screening was performed
for motifs deposited in the Transfac, JASPAR, UniPROBE, and
PDI databases. Moreover, de novo motifs where identified by
using MDscan algorithm.
Nuclear Factor of Activated T-Cells
Reporter Assay
HEK293 cell lines were transfected with nuclear factor of
activated T-cells (NFAT)-luciferase reporter construct (Qiagen,
Germantown, MD, USA). The cells were cultured, according
to the manufacturer’s recommendations. The cells were treated
with varying concentrations of niclosamide for 24 h. NFAT
promoter activity was quantified with Dual-Luciferase Reporter
Assay System (Promega, Madison, WI, USA) by measuring the
firefly and renilla luciferase luminescences on an Infinite M2000
ProTM plate reader (Tecan). The ratio of firefly luciferase intensity
to renilla luciferase intensity yielded a measure for NFAT activity.
4https://dtp.cancer.gov
5http://cistrome.org
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The relative luminance for each sample was calculated as: firefly
luciferase luminescence/renilla luciferase luminescence. DMSO
treatment served as control. Normalized NFAT activity was
calculated by the formula: relative luciferase of sample/relative
luciferase of the DMSO control. The experiment was repeated
three times.
Statistical Analysis
Data were expressed as mean ± SD of three independent tests.
Statistical significance was determined using the Student’s t-test.
A p-value of less than 0.05 denoted significance in all cases.
Hierarchical cluster analysis was performed using the Ward’s
method (WinSTAT program, Kalmia, Cambridge, MA, USA).
RESULTS
Cytotoxicity Assay
The cytotoxic activity of niclosamide was tested on CCRF-CEM
and CEM/ADR5000 leukemia, RPMI-8226 multiple myeloma,
HT-29 colorectal cancer, MDA-MB-231 breast cancer, and A549
lung cancer cells, using resazurin assay. Niclosamide showed
varying activity towards the tested cell lines as shown in Figure 1.
It was most active against the hematological cancer cell lines
CCRF-CEM, CEM/ADR5000, and RPMI-8226, compared to
the solid tumor cell lines HT-29, MDA-MB-231, and A549.
The resistance ratio between the sensitive CCRF-CEM and
multidrug resistant CEM/ADR5000 cells was 1.24, indicating that
CEM/ADR5000 were sensitive to niclosamide.
ROS Assay
Cellular ROS levels were analyzed after niclosamide treatment
by H2DCFH-DA staining and flow cytometry. A clear
dose-dependent increase in cellular ROS levels was observed after
24 h incubation with niclosamide (Figure 2). Thus, niclosamide
can be regarded as a ROS inducer in acute lymphoblastic
leukemia cells.
Target Prediction
A total of 391 biological targets were identified for niclosamide
by the DRAR-CPI algorithm. Interestingly, GS, which is directly
involved in ROS metabolism, was among the predicted targets.
Niclosamide showed a docking score of −47.8 and a Z′-score
of −0.788 for GS. We therefore hypothesized that the binding
of niclosamide to GS and the subsequent inhibition of GSH
production played an important role in the increase of ROS after
treatment of cells.
Glutathione Assay
In order to test whether niclosamide affected GSH levels in the
sensitive and resistant cell lines, GSH assays were performed
after treatment of leukemia cells with different concentrations
of niclosamide. The cells were stained with monochlorobimane
and fluorescence was measured using flow cytometry. As
shown in Figure 3, niclosamide significantly reduced the
intracellular GSH levels in a dose-dependent manner in both
cell lines. However, the effect on sensitive CCRF-CEM cells was
slightly higher than the effect on the resistant CEM/ADR5000
cells, which is consistent with the results from the ROS
assay.
Molecular Docking
To predict the binding affinity of niclosamide to GS and
propose its binding site, we performed molecular docking.
The protein structure of GS was downloaded in PDB format,
processed using Autodock Tools and finally converted to PDBQT
format. A grid box was then constructed. Energies at each
grid point were then evaluated for each atom type present
in the ligand. The values were used to predict the energy
of a particular ligand configuration. Docking was performed
for niclosamide on GS with Autodock4 using the Lamarckian
Algorithm. The corresponding binding energies and the number
of conformations in each cluster were attained from the docking
log files (dlg). As shown in Figure 4, the lowest binding energy for
niclosamide on GS was predicted to be −9.40 ± 0.01 kcal/mol,
which is a considerably low value. The amino acids involved
in the interaction included Ile143, Asn373, Tyr375, Met398,
Glu399, Ile401, Arg450, Lys452, and Ala457. Two of the amino
acids (Arg450 and Ala457) showed interactions with hydrogen
bonding.
Microscale Thermophoresis
Microscale thermophoresis was used to analyze the direct
interaction between GS and niclosamide (Figure 5). This method
is used to determine the binding affinity between a fluorescently
labeled protein and a non-labeled compound. Labeled GS
was titrated with different concentrations of niclosamide. An
equilibrium binding constant of 5.64 µM was obtained providing
evidence for direct binding of GS to niclosamide.
Microarray Analysis
To correlate the cellular responses of niclosamide with the
expression of the deregulated genes, we performed COMPARE
analyses. Using the NCI database, we correlated the microarray-
based transcriptome-wide mRNA expression of 60 tumor cell
lines with the log10IC50 values for niclosamide. We ran a standard
COMPARE, which correlated the lowest IC50 values with the
lowest mRNA expression levels of genes. We then ran a reverse
COMPARE which correlated the lowest IC50 values with the
highest gene expression level. The threshold for correlation
coefficients were R> 0.55 for standard COMPARE and R< -0.55
for reverse COMPARE (Supplementary Table S1). The genes that
showed good correlation with sensitivity to niclosamide included
those involved in signal transduction (TP53INP2, LAMTOP5,
PDE6G), lipid metabolism (SOAT, GMA2), regulation of cell
growth and development (MAP6, TANC2) and others. On the
other hand, genes that correlated with resistance included those
involved in signal transduction (MUC13, S100P, ARHGEF5,
LMO7), lipid metabolism and transport (PLA2G2A, CYP3A4,
APOM), protein synthesis (RPS16, E1F2S2) and others. The
mRNA expression values of these genes were used to perform
a hierarchical cluster analysis. The dendrogram of this cluster
analysis could be divided into five main cluster branches
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FIGURE 1 | Dose–response curves from the cytotoxicity assays of (A) hematological cancer cell lines (CCRF-CEM, CEM/ADR5000, and RPMI-8226) and
(B) solid tumor cell lines (HT-29, MDA-MB-231, and A549).
(Figure 6). Sensitivity or resistance to niclosamide and its
derivative were predicted by the distribution of cell lines in
the dendrogram according to their gene expression profiles. We
found a significant difference in the distribution of sensitive
and resistant cell lines between the branches of the dendrogram
(p = 8.66 × 10−5). The response of this cell line panel to
niclosamide and its derivative can therefore be determined by the
gene expression profile.
Promotor Binding Motif Analysis
To further determine the transcription factors and the
signaling pathways involved in the anticancer activity of
niclosamide, we performed promotor binding motif analysis.
To accomplish that, a set of 30 deregulated genes from the
microarray data were selected. As shown in Table 1, several
transcription factors might be involved in the cellular response
of cancer cells to niclosamide. Among them were CEBPA
and CEBPB (cell cycle regulation), RELA and CREL (NF-κB
pathway), TCF7L1 (Wnt/β-catenin signaling pathway), SMAD3
[transforming growth factor beta (TGF-β) signaling], FOXO1
and NFAT, all of which are involved in cancer initiation and
progression.
NFAT Reporter Assay
The NFAT was among the transcription factors that may
potentially bind to the gene promoters of deregulated genes
from the microarray data. In order to confirm this finding,
we performed an NFAT reporter assay. As shown in Figure 7,
niclosamide indeed caused a significant decrease in NFAT activity
in a dose dependent manner.
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FIGURE 2 | Effect of 24 h treatment with niclosamide (1.5 µM) on ROS levels in CCRF-CEM and CEM/ADR5000 cells. H2O2 (50 µM) was used as a
positive control (∗p < 0.05, ∗∗p < 0.01, compared to DMSO-treated control cells).
FIGURE 3 | Effect of niclosamide on glutathione levels in CCRF-CEM and CEM/ADR5000 cells. (A) Flow cytometric analysis of glutathione levels after
treatment with niclosamide (12 µM) for 24 h. (B) Statistical quantification of glutathione levels after treatment with different concentrations of niclosamide (∗p < 0.05,
∗∗p < 0.01, compared to DMSO-treated control cells).
DISCUSSION
A major problem of anticancer therapy is the development of
MDR. Pgp, an energy dependent eﬄux pump, plays an important
role in the development of MDR. Clinical studies have shown
that the overexpression of Pgp in cancer cells is associated
with poor prognosis (Bellamy, 1996). This protein transports
chemotherapeutic drugs that are central to many anticancer
regimens (Allen et al., 2000). Niclosamide showed cytotoxic
effects against various types of cancer (Li et al., 2014). Our
cytotoxicity assay results on the hematological, breast, lung,
and colorectal cancer cell lines, showed that niclosamide is
more active against the three hematological cell lines, compared
to the solid tumor cell lines cell lines, which were more
resistant. However, to the best of our knowledge, the effect of
niclosamide on MDR cancer has never been investigated, as of
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FIGURE 4 | Binding of niclosamide at the ATP binding domain of glutathione synthetase (GS). Hydrogen bond forming amino acids are shown in red.
FIGURE 5 | Characterization of binding affinity of niclosamide labeled GS using microscale thermophoresis.
yet. Interestingly we have found niclosamide to be active against
both the sensitive and MDR (Pgp-overexpressing) leukemia
cells. The resistance ratio was found to be 1.24, indicating that
niclosamide shows significant cytotoxic activity against leukemia
cells that display the MDR phenotype. The reason may be due to
its rapid uptake and the effective bypassing of Pgp, leading to its
higher intracellular accumulation and effectiveness. To the best
of our knowledge, we report for the first time that niclosamide is
active against MDR cancer cells.
ROS are highly reactive chemical entities including radicals,
ions or molecules that have a single unpaired electron in
their outermost shell of electrons (Liou and Storz, 2010).
The use of agents that significantly increase ROS represents
an effective strategy to kill cancer cells. Thus, a common
approach to treat cancer represents the application of agents with
strong pro-oxidant properties. Such agents would either directly
generate ROS or inhibit the antioxidant systems in the cell. This
will lead to an increase of ROS levels above the threshold, with
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FIGURE 6 | Dendrogram of hierarchical cluster analysis (Ward’s method) obtained from microarray-based mRNA expression profiles of genes
obtained from the NCI database correlating with niclosamide.
the subsequent induction of apoptosis and cell death (Ivanova
et al., 2013). Niclosamide is known to increase ROS levels in
cancer cells, including acute myeloid leukemia and lung cancer
cells (Wartenberg et al., 2005; Jin et al., 2010; Lee et al., 2014;
Liao et al., 2015). However, the mechanism behind this effect
has not been previously investigated. Our results showed that
niclosamide also caused the elevation of ROS levels in both
the sensitive and MDR leukemia cells. In an effort to elucidate
TABLE 1 | Transcription factors for which promoter motifs are found in the genes identified by COMPARE analysis.
Clusters Factor Z-score −10∗log (p-value) Clusters Factor Z-score −10∗log (p-value)
1. EmBP-1b −4.81 140.979 18. Pax-4 −3.543 85.274
Opaque-2 −3.995 103.405 19. MAF −3.523 84.535
2. ZNF766 −4.459 123.985 20. RFX1 −3.496 83.506
3. GCR1 −4.445 123.338 21. THRAP6 −3.443 81.539
4. CEBPB −4.158 110.418 22. bZIP911 −3.374 79.016
5. REL −4.09 107.455 23. Smad3 −3.35 78.123
c-Rel −3.438 81.363 24. NAC69-1 −3.347 78.039
6. Gat4 −4.083 107.159 25. FOXO1 −3.337 77.664
7. TCF7L1 −4.025 104.642 26. E2A|TCF3 −3.292 76.045
8. Zfp105 −3.969 102.289 27. PBF1 −3.288 75.932
9. Tcfap2e −3.95 101.515 28. POU6F1 −3.253 74.699
10. CEBPA −3.808 95.674 29. NF-AT −3.246 74.44
11. IRF-2 −3.789 94.879 ESE1|ELF3 −3.177 72.038
12. ATF6 −3.688 90.89 30. Elk1 −3.201 72.867
ROM −3.482 82.969 31. PTF1-beta −3.196 72.707
13. CPRF-1 −3.367 78.765 32. Zic2 −3.164 71.599
14. CPRF-3 −3.204 72.955 33. GCR1 −3.119 70.039
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FIGURE 7 | Effect of 24 h treatment with various concentrations of niclosamide on NFAT signaling activity. Results shown are the mean values ± SD of
three independent experiments (∗p < 0.01, compared to DMSO-treated control cells).
the mechanism by which niclosamide elevated ROS levels, we
identified GS as a possible target of niclosamide. GS is a key role
player in GSH synthesis, as it catalyzes the formation of GSH
from γ-glutamylcysteine and glycine, and therefore determines
the overall GSH synthetic capacity in certain tissues, especially
under stressful conditions (Lu, 2013). GSH is one of the most
important antioxidants in the cell. It plays several vital roles
including the maintenance of the redox state, drug detoxification,
and cellular protection from damage by free radicals, peroxides,
and toxins (Singh et al., 2012). It is involved in DNA repair
and apoptosis (Ichijo et al., 1997; Izbicka et al., 1997; Harwaldt
et al., 2002), and is clearly associated with cancer resistance to
chemotherapeutic agents (Capron et al., 2001; Harwaldt et al.,
2002). Niclosamide should therefore reduce the GSH levels in
cancer cells. Accordingly, we measured GSH levels in leukemia
cells after treatment with different concentrations of niclosamide.
The significant reduction in GSH levels indicates an inhibition
of GSH synthesis. As GSH is known to be involved in the
development of drug resistance (Townsend and Tew, 2003), the
inhibition of its synthesis probably plays a role in the activity of
niclosamide on MDR cells.
Molecular docking was used to confirm and clarify the
inhibitory effect of niclosamide on GS. This bioinformatical
tool is considered essential and valuable in drug discovery and
development. It gains its value from its ability to predict the
conformation of small-molecule ligands within the appropriate
target-binding site. It also estimates the ligand receptor binding
free energy involved in the molecular interaction (Meng et al.,
2011). Niclosamide gave a low binding energy indicating
a high affinity to GS. In order to validate the molecular
docking result, we studied the real interaction between GS
and niclosamide, using microscale thermophoresis. The results
showed good binding affinity, confirming our findings. We can
therefore postulate that niclosamide is a possible inhibitor of
GS. Niclosamide is therefore expected to inhibit the synthesis of
GSH in cancer cells causing a reduction of GSH levels shown
by the GSH assays. This then leads to the reduction in the ROS
scavenging effects of GSH, causing the increased accumulation of
ROS in cancer cells. A crystallographic study of the interaction
of GS with ATP revealed that Ile143, Tyr375, Met398, Glu399,
Ile401, and Lys452 contribute to the interaction between GS and
ATP (Polekhina et al., 1999; Dinescu et al., 2004). Accordingly,
niclosamide inhibits GS activity by competitively binding to the
ATP binding site, and therefore blocks the interaction with ATP.
Interestingly GS inhibitors have not been described in previous
studies. Niclosamide is therefore the first compound reported to
cause inhibition of GS.
The genes identified by the microarray-based COMPARE
analyses that showed good correlation with the cellular response
of niclosamide included those involved in lipid metabolism,
signal transduction, regulation of cell growth and development,
protein synthesis, and others. The result of the hierarchical cluster
analysis showed a significant difference in the distribution of
sensitive and resistant cell lines between the branches of the
dendrogram. The response of this cell line panel to niclosamide
can therefore be determined by the gene expression profile.
Inhibitors of lipogenic enzymes are quite active and efficient
anticancer agents. Several other compounds that target lipid and
cholesterol metabolism and homeostasis have shown relevant
anticancer activity (Beloribi-Djefaflia et al., 2016). According to
our findings from the microarray data analysis, lipid metabolism
might play a central role in the cytotoxic activity of niclosamide
against cancer cells. Further studies are required to confirm this
mechanism of action. These would include the determination of
the effect of niclosamide on the levels of lipogenic enzymes and
on the amounts of total lipid, total cholesterol and triglyceride in
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cancer cells. It is worth noting that none of the ABC transporters
was found to be associated with resistance to niclosamide. This
is consistent with our finding that overexpression of Pgp is not
involved in the resistance to niclosamide. The promoter binding
motif analysis of the microarray data of niclosamide showed that
a number of transcription factors might potentially bind to these
gene promoters. Those that are related to cancer include CEBPA,
CEBPB, RELA, CREL, TCF7L1, NFAT, and SMAD3. Thus,
several signaling pathways would be involved in the anticancer
activity of niclosamide. These pathways include the NF-κB, Wnt,
NFAT, TGF-β, and forkhead box protein O (FOXO) signaling
pathways. In addition, the CCAAT/enhancer-binding protein
(CEBP) transcription factors, involved in cell cycle regulation,
might also play a role in the activity of niclosamide. In accordance
with our findings, niclosamide is known to exert anticancer
activity through inhibition of NF-κB and Wnt signaling pathways
(Li et al., 2014). Niclosamide is also known to inhibit mechanistic
target of rapamycin (mTOR) signaling (Fonseca et al., 2012).
The mTOR signaling pathway regulates FOXO activity as well as
TGF-β signaling (Mori et al., 2014; Yu et al., 2015). Furthermore,
it controls the ratio of CEBP isoform expression. It is therefore
possible that the effect of niclosamide on the expression of FOXO,
TGF-β, and CEBP regulated genes is through the inhibition of
mTOR signaling.
Previously, the effect of niclosamide on several signaling
pathways has been investigated (Li et al., 2014). Even though,
its effect on NFAT activity has not been studied yet. The NFAT
signaling pathway has an important role in the development
and function of the immune system. It is also involved in the
development of cardiac, skeletal muscle, and nervous systems.
This pathway is activated by increased calcium levels, resulting
from its release from the endoplasmic reticulum or its influx
through activated channels in the cell membrane. Recent findings
have shown that NFAT contributes to cancer development
and progression, including solid tumors and hematological
malignancies. NFAT signaling is also known to be persistently
active in mouse models of human leukemia (Medyouf and
Ghysdael, 2008). Inhibition of NFAT signaling pathway in
leukemia cells caused cell growth arrest and induction of
apoptosis in vitro and in vivo (Mancini and Toker, 2009). Due
to the importance of NFAT signaling in the progression of
leukemia and our finding from the promoter binding motif
analysis, we further investigated the effect of niclosamide on
NFAT signaling using a reporter cell line. We found for the
first time that niclosamide significantly inhibited NFAT signaling
in a dose-dependent manner. The inhibition of NFAT activity
may therefore lead to growth arrest and induction of apoptosis,
participating in the anticancer activity of niclosamide.
We conclude that niclosamide exhibits a great potential as
an anticancer agent. In this study niclosamide showed excellent
activity against MDR leukemia. Niclosamide may therefore have
the potential to solve the problem of MDR in cancer patients. The
findings of the present study indicate that the cytotoxic activity of
niclosamide is due to its targeting of several signaling pathways
in cancer cells. We identified the inhibition of GSH synthesis
and NFAT signaling as novel mechanisms for the anticancer
activity of niclosamide. The microarray data analyses showed that
the cellular response of a cancer type can be predicted by its
gene expression profile. These data also suggest the involvement
of lipid metabolism in the anticancer activity of niclosamide.
It is therefore reasonable to consider niclosamide as a clinical
candidate for the treatment of refractory MDR cancers.
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